We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Nearly 700,000 women across the country will take part in a world-leading trial to test how AI tools can be used to catch breast cancer cases earlier.
As with all products, the MHRA will keep its safety under close review.
This workbook was developed by the Health Inequalities National Support Teams (HINST) with 70 local authorities covering populations in England.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab (Imdylltra) to treat adult patients with small cell lung cancer (SCLC) that has spread throughout the lungs and/or to other parts of the...
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 30 October, approved the medicine sugemalimab (Eqjubi) to treat adult patients with a type of lung cancer called ‘non-small cell lung cancer’.
80,000 patients have received a quicker diagnosis or ruling out of cancer in 28 days between July 2024 and January 2025 compared to the previous year.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).